CNRS Technologies

Find the best CNRS technologies to boost your innovative project.

Les brevets les plus récents

You are a research scientist?

We can guide you through the whole technology transfer process.

See all our services

You are a corporate player?

Thanks to our expertise, our network and our know-how of the innovation ecosystem, we support you throughout your project.

Contact us

Follow our news and upcoming events

Discover CNRS technologies

Meet our team


Use of a crystal comprising DNA polymerase clamp factor for the conception of new antibiotics



Statut des brevets

European patent EP03291596.9 filed on June 27, 2003, entitled “Protein crystal comprising the processivity clamp factor of DNA polymerase and a ligand, and its uses”


Dominique BURNOUF
Philippe DUMAS
Shingo FUJII
Robert FUCHS

Statut commercial

Research agreement, exclusive or non exclusive licenses


Laboratoire de Cancérogénèse et Mutagénèse Moléculaire Structurale (CMMS – UPR 9003), Strasbourg, France.



A successful DNA replication process requires that the DNA polymerase becomes processive through its association, via a short peptide, with a processivity factor. A new approach is being developed to inhibit bacterial DNA replication by impeding this interaction. It relies on the co-crystallization of a complex containing the Escherichia coli processivity factor beta and the binding peptide from an E. coli DNA polymerase.
The present invention relates to the crystallization method, the crystal structure and the use of the atomic coordinates for the screening and the design of new antibacterial drugs.

Ref.: Structural and biochemical analysis of sliding clamp/ligand interactions suggest a competition between replicative and translesion DNA polymerases. Burnouf DY, Olieric V, Wagner J, Fujii S, Reinbolt J, Fuchs RP, Dumas P. J Mol Biol. 2004 Jan 30;335(5):1187-97.


This new approach in inhibiting bacterial DNA replication allows for the screening of new drugs for the treatment of bacterial diseases or diseases originating from DNA synthesis processes, such as fragile X syndrome, or proliferative disorders, such as cancers.

For further information, please contact us (Ref 85933-01)

Besoin de plus d'informations ?

Nous contacter


  • This field is for validation purposes and should be left unchanged.

Les brevets les plus récents